New York State Common Retirement Fund raised its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 30.7% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,216 shares of the biotechnology company’s stock after purchasing an additional 13,219 shares during the period. New York State Common Retirement Fund owned 0.27% of Ligand Pharmaceuticals worth $9,285,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the stock. Municipal Employees Retirement System of Michigan raised its position in shares of Ligand Pharmaceuticals by 6.4% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the biotechnology company’s stock worth $1,392,000 after acquiring an additional 510 shares in the last quarter. Matarin Capital Management LLC purchased a new position in Ligand Pharmaceuticals in the first quarter valued at approximately $7,714,000. Tygh Capital Management Inc. raised its holdings in Ligand Pharmaceuticals by 3.4% during the 1st quarter. Tygh Capital Management Inc. now owns 50,514 shares of the biotechnology company’s stock valued at $8,343,000 after acquiring an additional 1,677 shares during the period. BlackRock Inc. raised its holdings in Ligand Pharmaceuticals by 0.6% during the 1st quarter. BlackRock Inc. now owns 3,013,829 shares of the biotechnology company’s stock valued at $497,763,000 after acquiring an additional 16,869 shares during the period. Finally, 6 Meridian bought a new stake in Ligand Pharmaceuticals during the 1st quarter valued at $703,000.
Top 5 Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Joseph Griffin]
Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.
- [By Joseph Griffin]
ArQule (NASDAQ:ARQL)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. They currently have a $6.00 price target on the biotechnology company’s stock, up from their prior price target of $5.00. Needham & Company LLC’s price target suggests a potential upside of 134.38% from the company’s previous close.
- [By Max Byerly]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Ethan Ryder]
ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
- [By Joseph Griffin]
ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.
Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.
Top 5 Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Brian Orelli]
The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn't think a few months will really matter: "We don't really feel that's going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we're very well prepared to be ready to launch following approval."
- [By Stephan Byrd]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) looked to be in a two-horse race to develop TTR amyloidosis (ATTR) drugs. Alnylam recently got its drug Onpattro approved, while Ionis Pharmaceuticals and its marketing partner Akcea Therapeutics (NASDAQ:AKCA) should hear about Tegsedi by Oct. 6. Tegsedi was approved in the EU last month.
- [By Cory Renauer]
Taking a medical breakthrough from concept through commercial success is like ascending a mountain that grows taller and more treacherous with every setback. It's taken Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) 16 years to launch its first drug, so challenges have had plenty of time to take up positions along this company's path to a successful first launch.
- [By Cory Renauer]
After 16 years as a public company, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) finally got the go-ahead to launch its first product earlier this month. Onpattro is the first in a new class of drugs that alter gene expression, but Pfizer, Inc. (NYSE:PFE) just reported some impressive results with a possible competitor that works a lot differently.
Top 5 Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.58 million shares from the previous level of 10.61 million. Shares were last seen trading at $193.15, in a 52-week trading range of $163.31 to $201.23.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 11.32 million shares from the previous level of 10.78 million. Shares were last seen trading at $142.15, in a 52-week trading range of $141.09 to $217.00.
- [By Cory Renauer]
The Food and Drug Administration recently approved Aimovig from Amgen (NASDAQ:AMGN) and Novartis (NYSE:NVS), the first of several high-profile new drug candidates with a similar mode of action. Teva Pharmaceuticals Industries (NYSE:TEVA) and Eli Lilly (NYSE:LLY) have sent applications for similar drugs to the FDA and Alder's starting to look like a terrier that showed up to a bullfight.
- [By ]
Amgen (Nasdaq: AMGN) -- Amgen is a leading global biotech developer with a diverse product portfolio and promising development pipeline. The company has special expertise in cancer research and renal failure (kidney disease) treatments. Its biggest blockbuster is the anti-inflammatory drug Enbrel, used primarily for rheumatoid arthritis, which is in the top-five worldwide with annual sales of nearly $8 billion.
- [By Keith Speights]
Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) rank among the elite in the world of biotech. Both companies have long track records of success. Both generate huge cash flow, but both also face headwinds.
Top 5 Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By WWW.GURUFOCUS.COM]
For the details of Woodford Investment Management LLP's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Woodford+Investment+Management+LLP
These are the top 5 holdings of Woodford Investment Management LLPProthena Corp PLC (PRTA) - 11,557,614 shares, 37.95% of the total portfolio. Shares added by 0.25%Alkermes PLC (ALKS) - 5,270,428 shares, 27.32% of the total portfolio. Shares reduced by 30.52%Theravance Biopharma Inc (TBPH) - 10,898,879 shares, 23.64% of the total portfolio. Shares added by 1.41%Biogen Inc (BIIB) - 279,564 shares, 6.85% of the total portfolio. Shares reduced by 24.56%Evofem Biosciences Inc (EVFM) - 7,465,538 - [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.35 million shares from the previous 4.00 million. The stock recently traded at $342.33, within a 52-week range of $249.17 to $388.67.
- [By Todd Campbell]
Many companies could see share prices pop or drop based on fast-approaching news in these indications, but six companies could be particularly exciting for investors to keep tabs on from here. In this episode of The Motley Fool's Industry Focus Healthcare, host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss:
The imminent results for Biogen's (NASDAQ:BIIB) Alzheimer's disease moonshot; Why European regulators could make this a big year for bluebird bio (NASDAQ:BLUE); How targeting the cause of sickle-cell disease could pan out for Global Blood Therapeutics (NASDAQ:GBT); A new treatment for peanut allergy is around the corner thanks to Aimmune Therapeutics (NASDAQ:AIMT); Vertex Pharmaceuticals' (NASDAQ:VRTX) big opportunity to significantly boost its addressable market; and The news that could transform Duchenne's muscular dystrophy treatment and send Sarepta Therapeutics' (NASDAQ:SRPT) revenue soaring.A full transcript follows the video.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 4.29 million shares from the previous 4.73 million. The stock recently traded at $344.10, within a 52-week range of $249.17 to $370.57.
- [By Lisa Levin] Companies Reporting Before The Bell United Technologies Corporation (NYSE: UTX) is estimated to report quarterly earnings at $1.51 per share on revenue of $14.62 billion. The Coca-Cola Company (NYSE: KO) is expected to report quarterly earnings at $0.46 per share on revenue of $7.31 billion. Caterpillar Inc. (NYSE: CAT) is projected to report quarterly earnings at $2.07 per share on revenue of $11.93 billion. Verizon Communications Inc. (NYSE: VZ) is expected to report quarterly earnings at $1.11 per share on revenue of $31.22 billion. Lockheed Martin Corporation (NYSE: LMT) is estimated to report quarterly earnings at $3.42 per share on revenue of $11.28 billion. The Sherwin-Williams Company (NYSE: SHW) is projected to report quarterly earnings at $3.15 per share on revenue of $3.94 billion. Biogen Inc. (NASDAQ: BIIB) is expected to report quarterly earnings at $5.92 per share on revenue of $3.15 billion. 3M Company (NYSE: MMM) is estimated to report quarterly earnings at $2.52 per share on revenue of $8.26 billion. JetBlue Airways Corporation (NASDAQ: JBLU) is projected to report quarterly earnings at $0.2 per share on revenue of $1.75 billion. Eli Lilly and Company (NYSE: LLY) is expected to report quarterly earnings at $1.13 per share on revenue of $5.49 billion. Harley-Davidson, Inc. (NYSE: HOG) is estimated to report quarterly earnings at $0.88 per share on revenue of $1.25 billion. Corning Incorporated (NYSE: GLW) is expected to report quarterly earnings at $0.3 per share on revenue of $2.50 billion. Centene Corporation (NYSE: CNC) is projected to report quarterly earnings at $1.88 per share on revenue of $13.28 billion. The Travelers Companies, Inc. (NYSE: TRV) is estimated to report quarterly earnings at $2.77 per share on revenue of $6.75 billion. Wipro Limited (NYSE: WIT) is expected to report quarterly earnings at $0.07 per share on revenue of $2.16 billion. PACCAR Inc (NASDAQ: PCAR) is projected to
- [By Brian Orelli]
Data source: Alkermes.
What happened with Alkermes this quarter? Sales of opioid and alcohol-dependence drug Vivitrol increased 11% year over year as states including Michigan, Pennsylvania, California, Florida, and Kentucky increase coverage of the drug as a treatment option for patients suffering from substance-use disorder. Schizophrenia drug Aristada saw sales increase 72% year over year and 35% quarter over quarter, thanks to the launch of Aristada Initio, which helps patients get started on the drug while hospitalized. Alkermes estimates it captured 29% of new prescriptions for long-acting aripiprazole, the active ingredient in Aristada. Ampyra, which goes by Fampyra outside the U.S., brought in $38.8 million, basically flat year over year, which wasn't bad since a generic launched in the U.S. last year. Manufacturing and royalty revenues for Risperdal Consta, Invega Sustenna, and Invega Trinza were up about 4% year over year. Fourth-quarter revenue also included a one-time payment of $26.7 million, which came from the sale of certain royalty streams by Zealand Pharma to Royalty Pharma. In November, Alkermes reported positive data from a second phase-3 clinical trial for schizophrenia drug ALKS 3831 that showed patients taking the drug had lower weight gain than those taking olanzapine. In December, Alkermes and its partner Biogen (NASDAQ:BIIB) filed for Food and Drug Administration (FDA) approval of diroximel fumarate, which Biogen plans to market under the name Vumerity. In January, Alkermes got bad news from the FDA when the agency turned down the marketing application for its depression drug ALKS 5461.Image source: Getty Images.
No comments:
Post a Comment